🔴 Femasys is trading 6.27% down today as investors take profits after FDA pathway rally

Femasys is trading 6.27% down today at $2.54 as investors take profits following yesterday's significant rally. - Femasys surged 23.18% on August 19 after the FDA approved a modular PMA pathway for its investigational FemBloc. - The staged review does not authorize U.S. marketing; final clinical results and approval remain outstanding.